927
Participants
Start Date
November 30, 2011
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2021
Bevacizumab
15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
Paclitaxel
175 mg/m², iv on day 1 every 3 weeks for 6 cycles
Carboplatin
AUC 5, iv on day 1 every 3 weeks for 6 cycles
specialized pathology review (Germany only)
before randomization
Aalborg
Copenhagen
Herlev
Kuopio
Oulu
Tampere
Turku
Angers
Besançon
Blois
Bordeaux
Caen
Cahors
Clamart
Clermont-Ferrand
Créteil
Dax
Draguignan
Grenoble
Limoges
Lyon
Mougins
Nancy
Nantes
Nice
Nîmes
Orléans
Paris
Pau
Plérin
Poitiers
Quimper
Reims
Rouen
Saint-Herblain
Strasbourg
Toulouse
Vandœuvre-lès-Nancy
Vannes
Villejuif
Aachen
Arnsberg
Aschaffenburg
Augsburg
Bad Homburg
Berlin
Bochum
Bonn
Bottrop
Brandenburg
Bremen
Chemnitz
Coburg
Cologne
Deggendorf
Dessau
Dresden
Düsseldorf
Ebersberg
Eggenfelden
Erlangen
Essen
Esslingen am Neckar
Flensburg
Frankfurt/M.
Freiburg im Breisgau
Fürstenfeldbruck
Fürth
Georgsmarienhütte
Gera
Göttingen
Greifswald
Gütersloh
Halle
Hamburg
Hanau
Hanover
Heidelberg
Henstedt-Ulzburg
Hildesheim
Jena
Kaiserslautern
Karlsruhe
Kassel
Kiel
Krefeld
Lich
Limburg
Lübeck
Lüneburg
Magdeburg
Mainz
Mannheim
Marburg
Minden
München
Neumarkt
Neuss
Nordhausen
Offenbach
Offenburg
Oldenburg
Osnabrück
Ravensburg
Regensburg
Reutlingen
Rosenheim
Rostock
Rottweil
Saalfeld
Salzgitter
Schwäbisch Hall
Schweinfurt
Sigmaringen
Solingen
Stralsund
Stuttgart
Torgau
Trier
Tübingen
Ulm
Viersen
Wiesbaden
Witten
Wolfsburg
Worms
Bergen
Oslo
Trondheim
Falun
Uppsala
ARCAGY/ GINECO GROUP
OTHER
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
OTHER
AGO Study Group
OTHER